Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis

Multiple Sclerosis

Volumn 20, Issue 2, 2014, Pages 156-164

  Zhang, Y ^a   McClellan, M ^a   Efros, L ^a   Shi, D ^a   Bielekova, B ^b   Tang, M T ^a   Vexler, V ^a   Sheridan, J P ^a  

^a ABBVIE INC   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

CD25; Daclizumab; HLA DR; multiple sclerosis; regulatory T cell; Treg; trogocytosis

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; DACLIZUMAB; FC RECEPTOR; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL KILLING; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TROGOCYTOSIS; LOW DRUG DOSE; PHAGOCYTOSIS AND RELATED PHENOMENA;

CD25; DACLIZUMAB; HLA-DR; MULTIPLE SCLEROSIS; REGULATORY T CELL; TREG; TROGOCYTOSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MONOCYTES; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84893557371     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513494488     Document Type: Article

References (23)

1. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol. 2007 ; 27: 1-18
2. Adachi K, Kumamoto T, Araki S. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol. 1990 ; 28: 687-691
3. Greenberg SJ, Marcon L, Hurwitz BJ, et al. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med. 1988 ; 319: 1019-1020
4. Hofman FM, von Hanwehr RI, Dinarello CA, et al. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol. 1986 ; 136: 3239-3245
5. Sivieri S, Ferrarini AM, Gallo P. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls. Mult Scler. 1998 ; 4: 7-11
6. Trotter JL, Clifford DB, Anderson CB, et al. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. N Engl J Med. 1988 ; 318: 1206
7. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
8. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006 ; 103: 5941-5946
9. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 ; 9: 381-390
10. Gold R, Giovannoni G, Selmaj K, et al. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of daclizumab high-yield process monotherapy in relapsing multiple sclerosis: Primary results of the SELECT trial. New Engl J Med. 2013 ;:
11. Martin JF, Perry JS, Jakhete NR, et al. An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol. 2010 ; 185: 1311-1320
12. Sheridan JP, Zhang Y, Riester K, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler. 2011 ; 17: 1441-1448
13. Snyder JT, Shen J, Azmi H, et al. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007 ; 109: 5399-5406
14. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med. 2011 ; 17: 604-609
15. Joly E, Hudrisier D. What is trogocytosis and what is its purpose?. Nat Immunol. 2003 ; 4: 815
16. Beum PV, Mack DA, Pawluczkowycz AW, et al. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol. 2008 ; 181: 8120-8132
17. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol. 1997 ; 159: 3613-3621
18. Aucher A, Magdeleine E, Joly E, et al. Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells. Blood. 2008 ; 111: 5621-5628
19. Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007 ; 26: 1423-1433
20. HoWangYin KY, Alegre E, Daouya M, et al. Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci. 2010 ; 67: 1133-1145
21. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: Cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007 ; 109: 2040-2048
22. Taylor RP, Lindorfer MA. Drug insight: The mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheum. 2007 ; 3: 86-95
23. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012 ; 4: 145-153